Presentations -
-
HDAC inhibition involves CD26 expression on multiple myeloma cells via the c-Myc/Sp1-mediated promoter activation and overcomes therapeutic resistance by humanized antibody
Hiroko Nishida, Reiko Suzuki, Kiyora Nakajima, Michiie Sakamoto
EHA 2023 Hybrid Congress (Frankfurt, Germany) ,
2023.06,Poster presentation, European Hematology Association
-
HDAC inhibition involves CD26 induction on multiple myeloma cells via the c-Myc/Sp1-mediated promoter activation and overcomes therapeutic resistance by humanized antibody.
Hiroko Nishida, Reiko Suzuki, Kiyora Nakajima, Mutusmi Hayashi, Michiie Sakamoto
64th ASH Annual Meeting & Exposition (New Orleans, LA, USA) ,
2022.12,Poster presentation, American Society of Hematology
-
HDAC inhibition involves CD26 induction in myeloma cells via the Sp1-mediated promoter activation.
Hiroko Nishida, Reiko Suzuki, Mutsumi Hayashi, Michiie Sakamoto
84th Japanese Society of Hematology Annual Meeting (Fukuoka) ,
2022.10,Oral presentation (general), Japanese Society of Hematology
-
Isoform-selective HDAC inhibition up-regulates CD26 expression on multiple myeloma cells and augments cytotoxic efficacy by humanized monoclonal antibody.
Hiroko Nishida, Mari Fujiwara, Mutsumi Hayashi, Michiie Sakamoto
AACR Annual Meeting (New Orleans, LA, USA) ,
2022.04,Poster presentation, American Association for Cancer Research
-
Up-regulation of CD26 on myeloma cells by HDAC inhibition enhances the efficacy of humanized antibody
Hiroko Nishida, Mari Fujiwara, Chikao Morimoto, Michiie Sakamoto
83rd Japanese Society of Hematology, Annual Meeting (Sendai) ,
2021.09,Oral presentation (general), Japanese Society of Hematology
-
Humanized anti-CD26 monoclonal antibody clonogenic side population cells in multiple myeloma.
Hiroko Nishida, Mustumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada
81th Japanese Society of Hematology Annual Meeting (Tokyo International Forum, Tokyo) ,
2019.10,Oral presentation (general), Japanese Society of Hematology
-
CD26 is a potential therapeutic target by humanized monoclonal antibody in multiple myeloma.
Hiroko Nishida, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada
第108回日本病理学会総会 (東京) ,
2019.05,Oral presentation (general), 日本病理学会
-
ヒト化抗CD26抗体とTriptolideの抗体薬物複合体はRNA polymeraseを阻害する
山田 健人、林 睦、西田 浩子、坂本 亨宇
第107回病理学会総会 (ロイトン札幌) ,
2018.06,Poster presentation, 日本病理学会
-
CD26 is a potential therapeutic target by humanized monoclonal antibody in multiple myeloma
Hiroko Nishida, Mutsumi Hayashi, Hiroshi Suzuki, Michiel Sakamoto, Taketo Yamada
23rd Congress of the European Hematology Association (Stockholm, Sweden) ,
2018.06,Poster presentation, European Hematology Association
-
Humanized anti-CD26 monoclonal antibody has anti-myeloma efficacy for the treatment of multiple myeloma
Hiroko Nishida, Mutsumi Hayashi, Chikao Morimoto,Michiie Sakamoto, Taketo Yamada
59th American Society of Hematology Annual Meeting & Exposition (Georgia World Congress Center, Atlanta, GA, USA) ,
2017.12,Poster presentation, American Society of Hematology
-
Humanized anti-CD26 monoclonal antibody has a therapeutic potentiality against multiple myeloma
Hiroko Nishida, Mustumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada
79th Annual Meeting of the Japanese Society of Hematology (Tokyo International Folum, Tokyo) ,
2017.10,Oral presentation (general), Japanese Society of Hematology
-
Humanized anti-CD26 monoclonal antibody has therapeutic potential in osteolytic bone metastasis
Hiroko Nishida, Hiroshi Suzuki, Mutsumi Hayashi, Michiie Sakamoto, Taketo Yamada
15th Japanese Society of Medical Oncology Annual Meeting (神戸国際会議場、神戸) ,
2017.07,Oral presentation (general), the Japanese Society of Medical Oncology
-
Humanized anti-CD26 monoclonal antibody has therapeutic potential in multiple myeloma
Hiroko Nishida, Hiroshi Suzuki, Mutsumi Hayashi, Michie Sakamoto, Taketo Yamada
第57回リンパ網内系学会総会 (京王プラザホテル、東京) ,
2017.07,Poster presentation, 日本リンパ網内系学会
-
Novel Monoclonal Antibody Therapy Targeting CD26 in Multiple Myeloma
Hiroko Nishida, Hiroshi Suzuki, Mutsumi Hayashi, Michiie Sakamoto, Taketo Yamada
22nd Congress of the European Hematology Association (Madrid, Spain) ,
2017.06,Poster presentation, European Hematology Association
-
肝癌に対するヒト化抗CD26モノクローナル抗体の抗腫瘍効果
山田健人、西田 浩子、林 睦、間所裕子、坂元亨宇
第106回日本病理学会総会 (京王プラザホテル、東京) ,
2017.04,Oral presentation (general), 日本病理学会
-
Isolated central nervous system relapse in type II enteropathy-associated T cell lymphoma
Hiroko Nishida, Eri Mashima, Mami Hatano, masao Hori, Katsuyuki Obara
78th Annual Meeting of the Japanese Society of Hematology (パシフィコ横浜) ,
2016.10,Poster presentation, 日本血液学会
-
Isolated central nervous system relapse in type II enteropathy-associated T cell lymphoma
Hiroko Nishida, Eri Massima, mami Habano, Masao Hori, Katsumyuki Obara
14th the Japanese Society of Medical Oncology Annual Meeting (神戸国際会議場) ,
2016.07,Poster presentation, 日本臨床腫瘍学会
-
ヒト化抗CD26モノクローナル抗体とRNAポリメラーゼII阻害剤トリプトライドの複合体の抗腫瘍効果
林睦、間所裕子、西田浩子、坂本亨宇、山田健人
第105回日本病理学会総会 (仙台国際センター、宮城) ,
2016.05,Oral presentation (general), 日本病理学会
-
CD26 is a novel target for the treatment of tumor progression and its related osteolytic bone disease
Hiroko Nishida, Hiroshi Suzuki, Hiroko Madokoro, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada
57th American Society of Hematology Annual Meeting and Exposition (Orlando,Flolida, USA) ,
2015.12,Poster presentation, American Society of Hematology
-
Blockade of CD26 signaling using humanized antibody reduces myeloma cell growth and its bone disease.
Hiroko Nishida, Hiroko Madokoro, Hiroshi Suzuki, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada
77th Annual Meeting of the Japanese Society of Hematology (Kanazawa, Ishikawa, Japan) ,
2015.10,Oral presentation (general), Japanese Society of Hematology